PTO/SB/08A (06-03) Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. FIT & Debstitute for form 1449A/PTO

Application Number

First Named Inventor

Filing Date

Complete if Known

10/605,498

10/2/2003

Gleave et al.

INFORMATIO	N D	ISCL	.osl	JRE
STATEMENT	BY	APP	LICA	NT

Art Unit 1014 163 (use as many sheets as necessary) Examiner Name Sheet of 2 Attorney Docket Number UBC.P-031

			U.S. PATENT D	DOCUMENTS	
	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where
	No.	Number-Kind Code ² (Faces)	IVINI-DD-1111	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-		-	
	L	US-			
	<u> </u>	US-		1e	
	<u> </u>	US-			
		US-			•
	L	US-			
		US-			_
		US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	_
	├	Country Code - Number - Nina Code (Ir known)			or Relevant Figures Appear	Τ*
	-					
	 					<u> </u>
	 		_			_

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicants unique citation designation number (optional). See Kinds Codes of US PTO Patent Documents at www.upsto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English

language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

Complete if Known Application Number 10/605,498 Filing Date 10/2/2003 Gleave et al.

First Named Inventor STATEMENT BY APPLICANT Art Unit (use as many sheets as necessary) Examiner Name Sheet **Attorney Docket Number** UBC.P-031

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
DUB		BUBENDORF ET AL., Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays, Journal of the National Cancer Institute, 10/20/1999, Page(s) 1758-1764, Volume 91, Number 20	
		CORNFORD ET AL., Heat Shock Protein Expression Independently Predicts Clinical Outcome in Prostate Cancer, Cancer Research, 12/15/2000, Page(s) 7099-7105, Volume 60	
		HORMAN ET AL., Anti-Sense Inhibition of Small-Heat-Shock-Protein (HSP27) Expression in MCF-7 Mammary-Carcinoma Cells Induces Their Spontaneous Acquisition of A Secretory Phenotype, Int. J. Cancer, 3/17/1999, Page(s) 574-582, Volume 82	
		OESTERREICH ET AL., The Small Heat Shock Protein hsp27 is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines, Cancer Research, 10/1/1993, Page(s) 4443-4448, Volume 53	
		RICHARDS ET AL., Effect of Overexpression of the Small Heat Shock Protein HSP27 on the Heat and Drug Sensitivities of Human Testis Tumor Cells, Cancer Research, 5/15/1996, Page(s) 2448-2451, Volume 56	
		RONDEAUX ET AL., Effects of Antisense HSP27 Gene Expression in Osteosarcoma Cells, In Vitro Cell Dev. Biol Animal, 10/1/1997, Page(s) 655-658, Volume 33	
		WU ET AL., Expression of the 25-kDa Heat-Shock Protein (HSP27) Correlates with Resistance to the Toxicity of Cadmium Chloride, Mercuric Chloride, cis-Platinum(II)-Diammine Dichloride, or Sodium Arsenite in Mouse Embryonic Stem Cells Transfected with Sense or Antisense HSP27 cDNA, Toxicology and Applied Pharmacology, 7/18/1996, Page(s) 330-339, Volume 141	
y		YAMOTO ET AL., Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance, Cancer Letters, 4/2/2001, Page(s) 173-181, Volume 168	
•			

Examiner Signature Date Considered 47	18105
---------------------------------------	-------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet

Submitte form 1449A/PTO

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE duction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known	
Application Number	10/605,498	
Filing Date	10/2/2003	
First Named Inventor	Gleave et al.	
Art Unit	1614 V/3S	
Examiner Name	AHY HOWNAM	

Attorney Docket Number | UBC.P-031

			U.S. PATENT (DOCUMENTS	
	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.'	Number-Kind Code ²	1444-00-1111	Applicant or offer boodinent	Figures Appear
		US-			
		US∙			
		บร-			
		US-			
	i	US-			
		US-			
		US-			
	1	US-			,

2

		FORE	EIGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number*- Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
ans		WO 01/70976 A2	09/27/2001	Corixa Corporation		
-						

Examiner Signature	attbouran	Date Considered	412818

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of US PTO Patent Documents at www.upsto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it displays a valid OMB control number.

1 20 3 3

Substitute for	form 1449B/PTO				Complete if Known
	MATION			Application Number	10/605,498
	MATION D			Filing Date	10/2/2003
STATE	EMENT BY	APPLICA	NT	First Named Inventor	Gleave et al.
				Art Unit .	1014-1085
(0	Use as many sheets a	s necessary)		Examiner Name	A. BONTA-
Sheet	2	of	_ 2	Attorney Docket Number	UBC.P-031

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
arb		DATABASE WPI, Section Ch, Week 199737,1997, Publisher: Derwent Publications Ltd., London, GB, XP002272450	
Outrs		GARRIDO ET AL., Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells the Doxorubicin-protecting effect of HSP27, European Journal of Biochemistry, 1996, Page(s) 653-659, Volume 237, Number 3, XP001004835	
OURB		GOTHAM ET AL., Antisense and Sirna Technologies - SMI Conference, IDRUGS, 2003, Page(s) 211-214, Volume 6, Number 3, Publisher: Current Drugs LTD, GB, XP008026723	
ans		MORINO ET AL., Specific Regulation of HSPs in Human Tumor Cell Lines by Flavonoids, In Vivo - International Journal of In Vivo Research, 1997, Page(s) 265-270, Volume 11, Number 3,: XP009007378	
Outro		TAMM ET AL., Antisense therapy in oncology: new hope for an old idea?, Lancet, 2001, Page(s) 489-497, Volume 358, Number 9280, XP004299974	
		· ·	

Examiner Date A7.8 (Signature)			
Considered 1100 1	Examiner Signature		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial it reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in toll in combinance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.